<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453089</url>
  </required_header>
  <id_info>
    <org_study_id>VG-101-001</org_study_id>
    <nct_id>NCT00453089</nct_id>
  </id_info>
  <brief_title>VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women</brief_title>
  <official_title>A Phase I/II Dose Escalation Clinical Trial to Assess Safety and Efficacy of VG101 to Treat the Symptoms of Vulvar and Vaginal Atrophy in Post-Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bionovo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bionovo</source>
  <brief_summary>
    <textblock>
      To conduct a prospective, randomized, blinded, placebo controlled, dose escalation clinical&#xD;
      trial in 4 cohorts of 10 postmenopausal women (total N=40) aged 45 to 65 years with at least&#xD;
      one menopausal vaginal symptom, vaginal pH &gt; 5.0 and &gt; 20% parabasal vaginal epithelial&#xD;
      cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Aims:&#xD;
&#xD;
        1. the optimal dose of VG101 based on the highest of 4 proposed dose levels that is not&#xD;
           associated with unacceptable toxicity during 12 weeks of treatment. Toxicity will be&#xD;
           based on National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events&#xD;
           (CTCAE), version 3. Unacceptable toxicity will be defined as the occurrence of any Grade&#xD;
           3, 4, of 5 toxicity that is possibly or probably associated with study drug or any other&#xD;
           unacceptable toxicity as determined by the Data and Safety Monitoring Board.&#xD;
&#xD;
        2. Specific potential adverse effects of VG101&#xD;
&#xD;
      Secondary Aims:&#xD;
&#xD;
        1. the preliminary efficacy of VG101 to:&#xD;
&#xD;
             -  relieve vulvar and/or vaginal dryness,&#xD;
&#xD;
             -  relieve vulvar and/or vaginal irritation&#xD;
&#xD;
             -  relieve vulvar and/or vaginal itching&#xD;
&#xD;
             -  relieve vulvar and/or vaginal discharge&#xD;
&#xD;
             -  relieve dyspareunia&#xD;
&#xD;
             -  improve sexual function&#xD;
&#xD;
             -  relieve dysuria&#xD;
&#xD;
             -  reduce frequency of urinary incontinence&#xD;
&#xD;
             -  improve quality of life&#xD;
&#xD;
             -  improve the physical examination assessment of vaginal atrophy&#xD;
&#xD;
             -  reduce vaginal fluid pH&#xD;
&#xD;
             -  improve the proportion of superficial vaginal epithelial cells&#xD;
&#xD;
        2. participant adherence to VG101 administration&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in self-reported symptoms of vaginal atrophy from baseline to 12 weeks</measure>
    <time_frame>4 and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in percent superficial vaginal epithelial cells from baseline 12 weeks</measure>
    <time_frame>4 and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the pH of vaginal secretions from baseline to 12 weeks</measure>
    <time_frame>4 and 12 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Vaginal Atrophy</condition>
  <condition>Vulvar Atrophy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VG101</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women between the ages of 45 and 65&#xD;
&#xD;
          2. Postmenopausal documented by: (a) at least one year of amenorrhea; (b) 6- 12 months of&#xD;
             amenorrhea with serum FSH &gt; 40 IU/ml; (c) 6 weeks post-surgical bilateral oophorectomy&#xD;
             with or without hysterectomy, or (d) hysterectomy with serum FSH levels &gt; 40 IU/ml.&#xD;
&#xD;
          3. Self-report at least one moderate to severe symptom of vulvar or vaginal atrophy from&#xD;
             the following list:&#xD;
&#xD;
               -  Vaginal dryness (none, mild, moderate or severe)&#xD;
&#xD;
               -  Vaginal and/or vulvar discomfort (none, mild, moderate, severe)&#xD;
&#xD;
               -  Vaginal and/or vulvar irritation (none, mild, moderate, severe)&#xD;
&#xD;
               -  Vaginal itching (none, mild, moderate, severe)&#xD;
&#xD;
               -  Vaginal pain associated with sexual activity (none, mild, moderate or severe)&#xD;
&#xD;
          4. &lt; 5% superficial cells on vaginal cytologic smear.&#xD;
&#xD;
          5. Vaginal pH &gt;5.0&#xD;
&#xD;
          6. Willing to use an intravaginal cream containing Chinese herbs for the treatment of&#xD;
             vaginal symptoms.&#xD;
&#xD;
          7. Provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of breast, uterine or ovarian cancer or melanoma.&#xD;
&#xD;
          2. Abnormal mammogram or breast examination within the last 9 months suggestive of&#xD;
             cancer.&#xD;
&#xD;
          3. Abnormal Pap smear or pelvic examination within the last 9 months suggestive of&#xD;
             cancer.&#xD;
&#xD;
          4. Any uterine or vaginal bleeding within the six months prior to enrollment (except&#xD;
             following the screening Pap smear).&#xD;
&#xD;
          5. Double-wall endometrial thickness that exceeds 5 mm measured on transvaginal&#xD;
             ultrasound.&#xD;
&#xD;
          6. Pregnant or lactating.&#xD;
&#xD;
          7. Use of any vaginal moisturizer (Replens, KY Silk-E, Astroglide Silken Secret,&#xD;
             Senselle) within 30 days of screening.&#xD;
&#xD;
          8. Use of any oral, transdermal, vaginal, or systemic estrogen or estrogen/progestin&#xD;
             product within 30 days of screening.&#xD;
&#xD;
          9. Use of raloxifene, tamoxifen or aromatase inhibitors within 12 weeks of screening.&#xD;
&#xD;
         10. Current urinary tract infection (dipstick urinalysis positive for leukocyte estrace,&#xD;
             nitrates or blood)&#xD;
&#xD;
         11. History of cardiovascular disease.&#xD;
&#xD;
         12. History of venous thromboembolic disease.&#xD;
&#xD;
         13. Use of another investigational agent within 12 weeks of screening.&#xD;
&#xD;
         14. Any medical or psychiatric condition that, in the investigator's opinion, would&#xD;
             preclude the participant from completing questionnaires or measures, adhering to the&#xD;
             protocol or completing the trial, including limited English literacy, severe illness,&#xD;
             plans to move, substance abuse, significant psychiatric problems, or dementia.&#xD;
&#xD;
         15. No access to a telephone&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Tagliaferri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bionovo, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Holly Richter, M.D., PhD</last_name>
      <phone>205-934-3180</phone>
      <email>hrichter@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Holly Richter, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Deborah Grady, M.D., MPH</last_name>
      <phone>415-353-9748</phone>
      <email>Deborah.Grady@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>George Sawaya, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>March 26, 2007</study_first_submitted>
  <study_first_submitted_qc>March 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2007</study_first_posted>
  <last_update_submitted>February 6, 2012</last_update_submitted>
  <last_update_submitted_qc>February 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2012</last_update_posted>
  <responsible_party>
    <name_title>Mary Tagliaferri, MD</name_title>
    <organization>Bionovo, Inc</organization>
  </responsible_party>
  <keyword>Chinese Herbs</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Vaginal Atrophy</keyword>
  <keyword>Vulvar Atrophy</keyword>
  <keyword>Symptoms</keyword>
  <keyword>Bionovo</keyword>
  <keyword>VG101</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

